Phathom Pharmaceuticals, is a US biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada. Vonoprazan is a novel, orally active potassium competitive acid blocker (P-CAB) discovered and developed by Takeda and marketed by both Takeda and Otsuka in Japan since 2015. P-CABs are a class of drug that competitively block the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump).

Phathom recently raised approximately $182m in a Nasdaq IPO with ticker: PHAT. Abingworth partner Andrew Sinclair was an observer on the board for Abingworth prior to the IPO.

LocationMenlo Park, CA, USA
CEOTerrie Curran